La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Mayinglong Pharmaceutical Group Performance dei guadagni passati
Il passato criteri di controllo 2/6
Mayinglong Pharmaceutical Group has been growing earnings at an average annual rate of 9.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.5% per year. Mayinglong Pharmaceutical Group's return on equity is 11.5%, and it has net margins of 13.9%.
Informazioni chiave
9.7%
Tasso di crescita degli utili
9.6%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 10.9% |
Tasso di crescita dei ricavi | 7.5% |
Rendimento del capitale proprio | 11.5% |
Margine netto | 13.9% |
Prossimo aggiornamento sui guadagni | 24 Aug 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You
Aug 19Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 24Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet
Jun 19Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%
May 07Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel
Mar 22Ripartizione dei ricavi e delle spese
Come Mayinglong Pharmaceutical Group guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
31 Mar 24 | 3,259 | 453 | 874 | 69 |
31 Dec 23 | 3,137 | 443 | 829 | 69 |
30 Sep 23 | 3,194 | 481 | 930 | 67 |
30 Jun 23 | 3,245 | 488 | 938 | 71 |
31 Mar 23 | 3,416 | 529 | 906 | 77 |
31 Dec 22 | 3,532 | 479 | 896 | 78 |
30 Sep 22 | 3,640 | 513 | 838 | 79 |
30 Jun 22 | 3,644 | 482 | 849 | 72 |
31 Mar 22 | 3,473 | 485 | 829 | 70 |
31 Dec 21 | 3,385 | 465 | 821 | 67 |
30 Sep 21 | 3,587 | 457 | 783 | 68 |
30 Jun 21 | 3,479 | 439 | 794 | 70 |
31 Mar 21 | 3,317 | 427 | 782 | 60 |
31 Dec 20 | 2,792 | 419 | 678 | 56 |
30 Sep 20 | 2,518 | 396 | 639 | 54 |
30 Jun 20 | 2,411 | 378 | 614 | 51 |
31 Mar 20 | 2,431 | 336 | 597 | 53 |
31 Dec 19 | 2,705 | 360 | 663 | 55 |
30 Sep 19 | 2,528 | 349 | 678 | 45 |
30 Jun 19 | 2,400 | 290 | 658 | 44 |
31 Mar 19 | 2,311 | 241 | 635 | 41 |
31 Dec 18 | 2,198 | 176 | 622 | 41 |
30 Sep 18 | 2,152 | 205 | 610 | 43 |
30 Jun 18 | 2,041 | 248 | 578 | 61 |
31 Mar 18 | 1,861 | 302 | 562 | 49 |
31 Dec 17 | 1,751 | 320 | 555 | 38 |
30 Sep 17 | 1,884 | 279 | 533 | 28 |
30 Jun 17 | 1,937 | 266 | 538 | 0 |
31 Mar 17 | 2,013 | 257 | 525 | 0 |
31 Dec 16 | 2,103 | 250 | 510 | 0 |
30 Sep 16 | 1,924 | 245 | 499 | 0 |
30 Jun 16 | 1,893 | 238 | 475 | 0 |
31 Mar 16 | 1,833 | 230 | 480 | 0 |
31 Dec 15 | 1,784 | 223 | 482 | 0 |
30 Sep 15 | 1,739 | 207 | 476 | 0 |
30 Jun 15 | 1,657 | 215 | 470 | 0 |
31 Mar 15 | 1,642 | 203 | 480 | 0 |
31 Dec 14 | 1,621 | 201 | 474 | 0 |
30 Sep 14 | 1,607 | 205 | 489 | 0 |
30 Jun 14 | 1,623 | 199 | 481 | 0 |
31 Mar 14 | 1,605 | 188 | 482 | 0 |
31 Dec 13 | 1,602 | 186 | 483 | 0 |
30 Sep 13 | 1,584 | 189 | 480 | 0 |
Guadagni di qualità: 600993 ha guadagni di alta qualità.
Margine di profitto in crescita: 600993's current net profit margins (13.9%) are lower than last year (15.5%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 600993's earnings have grown by 9.7% per year over the past 5 years.
Accelerare la crescita: 600993's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Guadagni vs Settore: 600993 had negative earnings growth (-14.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendimento del capitale proprio
ROE elevato: 600993's Return on Equity (11.5%) is considered low.